Methods of treating hematological disorders with quinazolinone compounds in selected patients

• 收藏
• 分享

专利权人:

Inc.;Calistoga Pharmaceuticals

发明人:

Lannutti, Brian,Miller, Langdon,Webb, Heather

申请号：

AU2011265258

公开号：

AU2011265258A1

申请日:

2011.06.10

申请国别(地区):

AU

年份:

2013

代理人:

摘要：

This disclosure relates to methods of selecting a subset of subjects having a hematological disorder and treating the selected group with a PI3K-delta inhibitor. In particular, the methods disclose evaluating levels of characteristic chemokine biomarkers, such as CCL2, CCL3, CCL4, CCL5, CXCL13, CCL17, CCL22, or TNF-alpha to select subjects that would have a greater chance of benefiting from treatment with a PI3K-delta inhibitor. The PI3K-delta inhibitors disclosed in this application are a type of quinazolinone-purinyl family of compounds.

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/